• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Deciphera Pharmaceuticals, Inc.

    < Previous 1 2 Next >
    U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
    From Deciphera Pharmaceuticals, Inc.
    Via Business Wire
    Tickers DCPH
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.